Enveric Biosciences Reports Full-Year 2021 Financial Results

 

Enveric Biosciences Inc. ENVB reported its financial results for the full year ended December 31, 2021.

2021 Financial Results

Comprehensive net loss for the year was $48.8 million, including $36.3 million in net non-cash expenses, with a basic and diluted loss per share of $2.07, as compared to a comprehensive net loss of $7.0 million with basic and diluted loss per share of $1.19 per share for the previous year.

Net cash used in operations for 2021 was $11.5 million consisting of the net loss, adjusted by a net of $36.3 million in non-cash expenses and changes in asset and liability balances of $1.2 million.

As of December 31, 2021, the Company had cash and cash equivalents of $17.4 million and working capital of $15.3 million. Subsequent to December 31, 2021, the company reportedly raised an additional $10 million.

Other highlights from 2021 include:

  • The company announced positive preclinical data for the EV102 radiodermatitis drug candidate, a cannabidiol (CBD) based product.
  • In November, Enveric was included in the AdvisorShares Psychedelics ETF PSIL.
  • In December, Bob Dagher, MD, was appointed as chief medical officer.

Dr. Joseph Tucker, Enveric’s CEO commented: “With the acquisition of MagicMed in September 2021, we immediately began moving forward with the clinical development strategy of our next-generation treatments and therapies for mental health. We find ourselves strategically positioned with an experienced team of industry professionals, collaborative partners including the University of Calgary, a growing intellectual property portfolio, and a robust Central Nervous System pipeline of promising drug candidates."

Dr. Joseph Tucker will be presenting at the Benzinga Psychedelics Capital Conference on April 19, 2022, at the Fontainebleau Miami Beach where we are bringing together leaders of the largest publicly-traded Psychedelics companies with investors from across North America.

Tickets for this first-of-its-kind gathering are still available here.

Photo by micheile on Unsplash

Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: CannabisEarningsNewsPenny StocksPsychedelicsMarketsAdvisorShares PsychedelicsEnveric Biosciences
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

The Benzinga Cannabis Capital Conference is coming to Florida

The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.

Get your tickets now on bzcannabis.com – Prices will increase very soon!


Loading...